| Literature DB >> 28953383 |
Petra Dvořáková1,2, Petr Bušek3, Tomáš Knedlík1,4, Jiří Schimer1,4, Tomáš Etrych5, Libor Kostka5, Lucie Stollinová Šromová3, Vladimír Šubr5, Pavel Šácha1,4, Aleksi Šedo3, Jan Konvalinka1,4.
Abstract
Proteases are directly involved in cancer pathogenesis. Expression of fibroblast activation protein (FAP) is upregulated in stromal fibroblasts in more than 90% of epithelial cancers and is associated with tumor progression. FAP expression is minimal or absent in most normal adult tissues, suggesting its promise as a target for the diagnosis or treatment of various cancers. Here, we report preparation of a polymer conjugate (an iBody) containing a FAP-specific inhibitor as the targeting ligand. The iBody inhibits both human and mouse FAP with low nanomolar inhibition constants but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and prolyl oligopeptidase. We demonstrate the applicability of this iBody for the isolation of FAP from cell lysates and blood serum as well as for its detection by ELISA, Western blot, flow cytometry, and confocal microscopy. Our results show the iBody is a useful tool for FAP targeting in vitro and potentially also for specific anticancer drug delivery.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28953383 DOI: 10.1021/acs.jmedchem.7b00767
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446